{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:12:22Z","timestamp":1791875542872,"version":"4.3.4"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"RVL Pharmaceuticals, Inc., an affiliate of Osmotica Pharmaceuticals plc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Blepharoptosis (ptosis) is among the most common disorders of the upper eyelid encountered in both optometric and ophthalmic practice. The unilateral or bilateral drooping of the upper eyelid that characterises ptosis can affect appearance and impair visual function, both of which can negatively impact quality of life. While there are several known forms of congenital ptosis, acquired ptosis (appearing later in life, due to a variety of causes) is the predominant form of the condition. This review summarises the prevalence, causes, identification, differential diagnosis, and treatment of acquired ptosis. Particular attention is paid to the differential diagnosis of acquired ptosis and emerging treatment options, including surgical and pharmacologic approaches.<\/jats:p>","DOI":"10.1038\/s41433-021-01547-5","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T16:02:37Z","timestamp":1619712157000},"page":"2468-2481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["A review of acquired blepharoptosis: prevalence, diagnosis, and current treatment options"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7084-4327","authenticated-orcid":false,"given":"Jason","family":"Bacharach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Freddo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"1547_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/ageing\/24.1.21","volume":"24","author":"WM Forman","year":"1995","unstructured":"Forman WM, Leatherbarrow B, Sridharan GV, Tallis RC. A community survey of ptosis of the eyelid and pupil size of elderly people. Age Ageing. 1995;24:21\u201324.","journal-title":"Age Ageing"},{"key":"1547_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.joco.2016.04.005","volume":"28","author":"H Hashemi","year":"2016","unstructured":"Hashemi H, Khabazkhoob M, Emamian MH, Yekta A, Jafari A, Nobovati P, et al. The prevalence of ptosis in an Iranian adult population. J Curr Ophthalmol. 2016;28:142\u20135.","journal-title":"J Curr Ophthalmol"},{"key":"1547_CR3","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/eye.2017.43","volume":"31","author":"MH Kim","year":"2017","unstructured":"Kim MH, Cho J, Zhao D, Woo KI, Kim YD, Kim S, et al. Prevalence and associated factors of blepharoptosis in Korean adult population: the Korea National Health and Nutrition Examination Survey. Eye. 2017;31:940\u20136.","journal-title":"Eye"},{"key":"1547_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/01676830.2011.638095","volume":"31","author":"MC Tan","year":"2012","unstructured":"Tan MC, Young S, Amrith S, Sundar G. Epidemiology of oculoplastic conditions: the Singapore experience. Orbit. 2012;31:107\u201313.","journal-title":"Orbit"},{"key":"1547_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00266-003-0127-5","volume":"27","author":"J Finsterer","year":"2003","unstructured":"Finsterer J. Ptosis: causes, presentation, and management. Aesthetic Plast Surg. 2003;27:193\u2013204.","journal-title":"Aesthetic Plast Surg"},{"key":"1547_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1177\/1090820X10374108","volume":"30","author":"CI Zoumalan","year":"2010","unstructured":"Zoumalan CI, Lisman RD. Evaluation and mangement of unilateral ptosis and avoiding contralateral ptosis. Aesthet Surg J. 2010;30:320\u20138.","journal-title":"Aesthet Surg J"},{"key":"1547_CR7","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.ajo.2007.02.022","volume":"143","author":"R McKean-Cowdin","year":"2007","unstructured":"McKean-Cowdin R, Varma R, Wu J, Hays RD, Azen SP, Los Angeles Latino Eye Study Group. Severity of visual field loss and health-related quality of life. Am J Ophthalmol. 2007;143:1013\u201323.","journal-title":"Am J Ophthalmol"},{"key":"1547_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/eye.2013.264","volume":"28","author":"HS Richards","year":"2014","unstructured":"Richards HS, Jenkinson E, Rumsey N, White P, Garrott H, Herbert H, et al. The psychological well-being and appearance concerns of patients presenting with ptosis. Eye. 2014;28:296\u2013302.","journal-title":"Eye"},{"key":"1547_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/IOP.0b013e31829a7288","volume":"29","author":"ST Alniemi","year":"2013","unstructured":"Alniemi ST, Pang NK, Woog JJ, Bradley EA. Comparison of automated and manual perimetry in patients with blepharoptosis. Ophthal Plast Reconstr Surg. 2013;29:361\u20133.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"1547_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/eye.2010.210","volume":"25","author":"SF Ho","year":"2011","unstructured":"Ho SF, Morawski A, Sampath R, Burns J. Modified visual field test for ptosis surgery (Leicester Peripheral Field Test). Eye. 2011;25:365\u20139.","journal-title":"Eye"},{"key":"1547_CR11","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0161-6420(93)31593-9","volume":"100","author":"DR Meyer","year":"1993","unstructured":"Meyer DR, Stern JH, Jarvis JM, Lininger LL. Evaluating the visual field effects of blepharoptosis using automated static perimetry. Ophthalmology. 1993;100:651\u20138.","journal-title":"Ophthalmology"},{"key":"1547_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0002-9394(14)70634-8","volume":"121","author":"VK Battu","year":"1996","unstructured":"Battu VK, Meyer DR, Wobig JL. Improvement in subjective visual function and quality of life outcome measures after blepharoptopsis surgery. Am J Ophthalmol. 1996;121:677\u201386.","journal-title":"Am J Ophthalmol"},{"key":"1547_CR13","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0161-6420(99)90354-8","volume":"106","author":"TJ Federici","year":"1999","unstructured":"Federici TJ, Meyer DR, Lininger LL. Correlation of the vision-related functional impairment associated with blepharoptosis and the impact of blepharoptosis surgery. Ophthalmology. 1999;106:1705\u201312.","journal-title":"Ophthalmology"},{"key":"1547_CR14","unstructured":"Freddo TF, Chaum E. Anatomy of the eye and orbit: the clinical essentials. 1st edn. Philadelphia: Wolters Kluwer Health; 2018."},{"key":"1547_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fneur.2017.00329","volume":"8","author":"AG Hamedani","year":"2017","unstructured":"Hamedani AG, Gold DR. Eyelid dysfunction in neurodegenerative, neurogenetic, and neurometabolic disease. Front Neurol. 2017;8:329.","journal-title":"Front Neurol"},{"key":"1547_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-0037-1598190","volume":"31","author":"MW Latting","year":"2017","unstructured":"Latting MW, Huggins AB, Marx DP, Giacometti JN. Clinical evaluation of blepharoptosis: distinguishing age-related ptosis from masquerade conditions. Semin Plast Surg. 2017;31:5\u201316.","journal-title":"Semin Plast Surg"},{"key":"1547_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/00002341-199903000-00005","volume":"15","author":"B Esmaeli-Gutstein","year":"1999","unstructured":"Esmaeli-Gutstein B, Hewlett BR, Pashby RC, Oestreicher J, Harvey JT. Distribution of adrenergic receptor subtypes in the retractor muscles of the upper eyelid. Ophthal Plast Reconstr Surg. 1999;15:92\u201399.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"1547_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/IOP.0000000000001095","volume":"34","author":"SJ Park","year":"2018","unstructured":"Park SJ, Jang SY, Baek JS, Chin S, Jang JW. Distribution of adrenergic receptor subtypes and responses to topical 0.5% apraclonidine in patients with blepharoptosis. Ophthalmic Plast Reconstr Surg. 2018;34:547\u201351.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"1547_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/IOP.0b013e3181462a2e","volume":"23","author":"BC Skibell","year":"2007","unstructured":"Skibell BC, Harvey JH, Oestreicher JH, Howarth D, Gibbs A, Wegrynowski T, et al. Adrenergic receptors in the ptotic human eyelid: correlation with phenylephrine testing and surgical success in ptosis repair. Ophthalmic Plast Reconstr Surg. 2007;23:367\u201371.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"1547_CR20","doi-asserted-by":"crossref","unstructured":"Custer PL Blepharoptosis. In: Yanoff M, Duker JS, (eds). Ophthalmology. 3 edn. (Elsevier, St Louis, 2008) 1397\u2013403.","DOI":"10.1016\/B978-0-323-04332-8.00234-1"},{"key":"1547_CR21","unstructured":"Kostick DA & Bartley GB Upper eyelid malpositions: congenital ptosis. In: Albert DM, Jakobiec FA, Azar DT, Gragoudas ES, (eds). Principles and practice of ophthalmology. 1. 2 edn. (W.B. Saunders, Philadelphia, 2000) 3460\u20138."},{"key":"1547_CR22","first-page":"5","volume":"6","author":"P Sudhakar","year":"2009","unstructured":"Sudhakar P, Vu Q, Kosoko-Lasaki O, Palmer M. Upper eyelid ptosis revisited. Am J Clin Med. 2009;6:5\u201314.","journal-title":"Am J Clin Med"},{"key":"1547_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1586\/17469899.2015.991389","volume":"10","author":"A Mokhtarzadeh","year":"2015","unstructured":"Mokhtarzadeh A, Harrison AR. Controversies and advances in the management of congenital ptosis. Expert Rev Ophthalmol. 2015;10:59\u201363.","journal-title":"Expert Rev Ophthalmol"},{"key":"1547_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3109\/01676830.2013.788673","volume":"32","author":"JM Lim","year":"2013","unstructured":"Lim JM, Hou JH, Singa RM, Aakalu VK, Setabutr P. Relative incidence of blepharoptosis subtypes in an oculoplastics practice at a tertiary care center. Orbit. 2013;32:231\u20134.","journal-title":"Orbit"},{"key":"1547_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1444-0938.2004.tb03139.x","volume":"87","author":"JHJ Thean","year":"2004","unstructured":"Thean JHJ, McNab AA. Blepharoptosis in RGP and PMMA hard contact lens wearers. Clin Exp Optom. 2004;87:11\u201314.","journal-title":"Clin Exp Optom"},{"key":"1547_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jcjo.2011.06.010","volume":"46","author":"I Bleyen","year":"2011","unstructured":"Bleyen I, Hiemstra CA, Devogelaere T, van den Bosch WA, Wubbels RJ, Paridaens DA. Not only hard contact lens wear but also soft contact lens wear may be associated with blepharoptosis. Can J Ophthalmol. 2011;46:333\u20136.","journal-title":"Can J Ophthalmol"},{"key":"1547_CR27","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1097\/SCS.0000000000001876","volume":"26","author":"K Hwang","year":"2015","unstructured":"Hwang K, Kim JH. The risk of blepharoptosis in contact lens wearers. J Craniofac Surg. 2015;26:e373\u2013e374.","journal-title":"J Craniofac Surg"},{"key":"1547_CR28","first-page":"219","volume":"13","author":"T Kitazawa","year":"2013","unstructured":"Kitazawa T. Hard contact lens wear and the risk of acquired blepharoptosis: a case-control study. Eplasty. 2013;13:219\u201324.","journal-title":"Eplasty"},{"key":"1547_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/asj\/sju070","volume":"35","author":"N Satariano","year":"2015","unstructured":"Satariano N, Brown MS, Zwiebel S, Guyuron B. Environmental factors that contribute to upper eyelid ptosis: a study of identical twins. Aesthet Surg J. 2015;35:235\u201341.","journal-title":"Aesthet Surg J"},{"key":"1547_CR30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00417-018-4130-6","volume":"257","author":"Y Wang","year":"2019","unstructured":"Wang Y, Lou L, Liu Z, Ye J. Incidence and risk of ptosis following ocular surgery: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2019;257:397\u2013404.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1547_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/ICU.0000000000000218","volume":"27","author":"KJ Godfrey","year":"2016","unstructured":"Godfrey KJ, Korn BS, Kikkawa DO. Blepharoptosis following ocular surgery: identifying risk factors. Curr Opin Ophthalmol. 2016;27:31\u201337.","journal-title":"Curr Opin Ophthalmol"},{"key":"1547_CR32","doi-asserted-by":"publisher","first-page":"895","DOI":"10.4103\/0301-4738.176032","volume":"63","author":"V Koh","year":"2015","unstructured":"Koh V, Tatsios J, Chew PT, Amrith S. Comparison of incidence of ptosis after combined phacotrabeculectomy with mitomycin C and phacoemulsification. Indian J Ophthalmol. 2015;63:895\u20138.","journal-title":"Indian J Ophthalmol"},{"key":"1547_CR33","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S0161-6420(86)33529-2","volume":"93","author":"JV Linberg","year":"1986","unstructured":"Linberg JV, McDonald MB, Safir A, Googe JM. Ptosis followoing radial keratectomy: performed using a rigid eyelid speculum. Ophthalmology. 1986;93:1509\u201312.","journal-title":"Ophthalmology"},{"key":"1547_CR34","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0886-3350(13)80807-3","volume":"16","author":"M Loeffler","year":"1990","unstructured":"Loeffler M, Solomon LD, Renaud M. Postcataract extraction ptosis: effect of the bridle suture. J Cataract Refract Surg. 1990;16:501\u20134.","journal-title":"J Cataract Refract Surg"},{"key":"1547_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/IJG.0000000000000174","volume":"24","author":"A Naruo-Tsuchisaka","year":"2015","unstructured":"Naruo-Tsuchisaka A, Maruyama K, Arimoto G, Goto H. Incidence of postoperative ptosis following trabeculectomy with mitomycin C. J Glaucoma. 2015;24:417\u201320.","journal-title":"J Glaucoma"},{"key":"1547_CR36","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/dsu.12463","volume":"40","author":"M Cavallini","year":"2014","unstructured":"Cavallini M, Cirillo P, Fundaro SP, Quartucci S, Sciuto C, Sito G, et al. Safety of botulinum toxin A in aesthetic treatments: a systemitc review of clinical studies. Dermatol Surg. 2014;40:525\u201336.","journal-title":"Dermatol Surg"},{"key":"1547_CR37","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/DSS.0000000000000386","volume":"41","author":"KD Steinsapir","year":"2015","unstructured":"Steinsapir KD, Groth MJ, Boxrud CA. Persistence of upper blepharoptosis after cosmetic botulinum toxin type A. Dermatol Surg. 2015;41:833\u201340.","journal-title":"Dermatol Surg"},{"key":"1547_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jns.2017.03.025","volume":"376","author":"S Wijemanne","year":"2017","unstructured":"Wijemanne S, Vijayakumar D, Jankovic J. Apraclonidine in the treatment of ptosis. J Neurol Sci. 2017;376:129\u201332.","journal-title":"J Neurol Sci"},{"key":"1547_CR39","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1136\/bjo.2003.029371","volume":"88","author":"HV Danesh-Meyer","year":"2004","unstructured":"Danesh-Meyer HV, Savino P, Sergott R. The correlation of phenylephrine 1% with hydroxyamphetamine 1% in Horner\u2019s syndrome. Br J Ophthalmol. 2004;88:592\u20133.","journal-title":"Br J Ophthalmol"},{"key":"1547_CR40","unstructured":"Reinhard E, Spampinato H. The OD\u2019s guide to ptosis workup. Rev Optom. 2020;157:68\u201373."},{"key":"1547_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1067\/mpa.2000.106204","volume":"4","author":"FD Ellis","year":"2000","unstructured":"Ellis FD, Hoyt CS, Ellis FJ, Jeffery AR, Sondhi N. Extraocular muscle responses to orbital cooling (ice test) for ocular myasthenia gravis diagnosis. J AAPOS. 2000;4:271\u201381.","journal-title":"J AAPOS"},{"key":"1547_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/IIO.0b013e31815726f5","volume":"47","author":"ME Gilbert","year":"2007","unstructured":"Gilbert ME, Savino PJ. Ocular myasthenia gravis. Int Ophthalmol Clin. 2007;47:93\u2013103.","journal-title":"Int Ophthalmol Clin"},{"key":"1547_CR43","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/IOP.0b013e3182523b7f","volume":"28","author":"AM Putterman","year":"2012","unstructured":"Putterman AM. Margin reflex distance (MRD) 1, 2, and 3. Ophthalmic Plast Reconstr Surg. 2012;28:308\u201311.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"1547_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/kjo.kjo_2_19","volume":"31","author":"M Pauly","year":"2019","unstructured":"Pauly M, Sruthi R. Ptosis: evaluation and management. Kerala J Ophthalmol. 2019;31:11\u201316.","journal-title":"Kerala J Ophthalmol"},{"key":"1547_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/IOP.0000000000000903","volume":"34","author":"A Barsegian","year":"2018","unstructured":"Barsegian A, Botwinick A, Reddy HS. The phenylephrine test revisited. Ophthalmic Plast Reconstr Surg. 2018;34:151\u20134.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"1547_CR46","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1001\/archfaci.9.6.413","volume":"9","author":"GJ Ben Simon","year":"2007","unstructured":"Ben Simon GJ, Lee S, Schwarcz RM, McCann JD, Goldberg RA. Muller\u2019s muscle-conjunctival resection for correction of upper eyelid ptosis: relationship between phenylephrine testing and the amount of tissue resected with final eyelid position. Arch Facial Plast Surg. 2007;9:413\u20137.","journal-title":"Arch Facial Plast Surg"},{"key":"1547_CR47","first-page":"173","volume":"21","author":"HJ Glatt","year":"1990","unstructured":"Glatt HJ, Fett DR, Putterman AM. Comparison of 2.5% and 10% phenylephrine in the elevation of upper eyelids with ptosis. Ophthalmic Surg. 1990;21:173\u20136.","journal-title":"Ophthalmic Surg"},{"key":"1547_CR48","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3109\/01676831003666447","volume":"30","author":"R Maheshwari","year":"2011","unstructured":"Maheshwari R, Maheshwari S. Muller\u2019s muscle resection for ptosis and relationship with levator and Muller\u2019s muscle function. Orbit. 2011;30:150\u20133.","journal-title":"Orbit"},{"key":"1547_CR49","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1016\/j.ophtha.2011.09.029","volume":"118","author":"KV Cahill","year":"2011","unstructured":"Cahill KV, Bradley EA, Meyer DR, Custer PL, Holck DE, Marcet MM, et al. Functional indications for upper eyelid ptosis and blepharoplasty surgery: a report by the American Academy of Ophthalmology. Ophthalmology. 2011;118:2510\u20137.","journal-title":"Ophthalmology"},{"key":"1547_CR50","first-page":"374","volume":"15","author":"SH Wong","year":"2015","unstructured":"Wong SH, Plant GT. How to interpret visual fields. Pr Neurol (Fort Wash Pa). 2015;15:374\u201381.","journal-title":"Pr Neurol (Fort Wash Pa)"},{"key":"1547_CR51","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ajo.2005.03.033","volume":"140","author":"GJ Ben Simon","year":"2005","unstructured":"Ben Simon GJ, Lee S, Schwarcz RM, McCann JD, Goldberg RA. External levator advancement vs M\u00fcller\u2019s muscle-conjunctival resection for correction of upper eyelid involutional ptosis. Am J Ophthalmol. 2005;140:426\u201332.","journal-title":"Am J Ophthalmol"},{"key":"1547_CR52","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0161-6420(89)32786-2","volume":"96","author":"AJ Berlin","year":"1989","unstructured":"Berlin AJ, Vestal KP. Levator aponeurosis surgery. A retrospective review. Ophthalmology. 1989;96:1033\u20136.","journal-title":"Ophthalmology"},{"key":"1547_CR53","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/eye.2001.247","volume":"15","author":"CA Cates","year":"2001","unstructured":"Cates CA, Tyers AG. Outcomes of anterior levator resection in congenital blepharoptosis. Eye (Lond). 2001;15:770\u20133.","journal-title":"Eye (Lond)"},{"key":"1547_CR54","first-page":"199","volume":"102","author":"BR Frueh","year":"2004","unstructured":"Frueh BR, Musch DC, McDonald H. Efficacy and efficiency of a new involutional ptosis correction procedure compared to a traditional aponeurotic approach. Trans Am Ophthalmol Soc. 2004;102:199\u2013206.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1547_CR55","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0002-9394(99)00064-1","volume":"127","author":"MJ Lucarelli","year":"1999","unstructured":"Lucarelli MJ, Lemke BN. Small incision external levator repair: technique and early results. Am J Ophthalmol. 1999;127:637\u201344.","journal-title":"Am J Ophthalmol"},{"key":"1547_CR56","first-page":"1056","volume":"90","author":"JJ Older","year":"1983","unstructured":"Older JJ. Levator aponeurosis surgery for the correction of acquired ptosis. Anal 113 Proced Ophthalmol. 1983;90:1056\u20139.","journal-title":"Anal 113 Proced Ophthalmol"},{"key":"1547_CR57","doi-asserted-by":"publisher","first-page":"e19038","DOI":"10.1097\/MD.0000000000019038","volume":"99","author":"E Pan","year":"2020","unstructured":"Pan E, Chen WL, Zhang SC, Chen Y, Yu JG. Mild to moderate blepharoptosis correction: Outcomes of levator aponeurosis posterior layer plication. Med (Baltim). 2020;99:e19038.","journal-title":"Med (Baltim)"},{"key":"1547_CR58","first-page":"354","volume":"17","author":"AM Putterman","year":"1986","unstructured":"Putterman AM, Fett DR. M\u00fcller\u2019s muscle in the treatment of upper eyelid ptosis: a ten-year study. Ophthalmic Surg. 1986;17:354\u201360.","journal-title":"Ophthalmic Surg"},{"key":"1547_CR59","unstructured":"Aetna, Inc. Eyelid surgery. Medical Policy Bulletin Number 0084. Updated 2019. http:\/\/www.aetna.com\/cpb\/medical\/data\/1_99\/0084.html."},{"key":"1547_CR60","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1001\/archopht.1990.01070130130043","volume":"108","author":"RL Anderson","year":"1990","unstructured":"Anderson RL, Jordan DR, Dutton JJ. Whitnall\u2019s sling for poor function ptosis. Arch Ophthalmol. 1990;108:1628\u201332.","journal-title":"Arch Ophthalmol"},{"key":"1547_CR61","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/01.IOP.0000143714.10858.D4","volume":"20","author":"MH Erb","year":"2004","unstructured":"Erb MH, Kersten RC, Yip CC, Hudak D, Kulwin DR, McCulley TJ. Effect of unilateral blepharoptosis repair on contralateral eyelid position. Ophthalmic Plast Reconstr Surg. 2004;20:418\u201322.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"1547_CR62","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/IOP.0000000000000938","volume":"34","author":"E Chou","year":"2018","unstructured":"Chou E, Liu J, Seaworth C, Furst M, Amato MM, Blaydon SM, et al. Comparison of revision rates on anterior- and posterior-approach ptosis surgery: a retrospective review of 1519 cases. Ophthal Plast Reconstr Surg. 2018;34:246\u201353.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"1547_CR63","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/01676830.2017.1383475","volume":"37","author":"K Katsoulos","year":"2018","unstructured":"Katsoulos K, Rallatos GL, Mavrikakis I. Scleral contact lenses for the management of complicated ptosis. Orbit. 2018;37:201\u20137.","journal-title":"Orbit"},{"key":"1547_CR64","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/01.ico.0000148311.94180.6b","volume":"24","author":"KW Pullum","year":"2005","unstructured":"Pullum KW, Whiting MA, Buckley RJ. Scleral contact lenses: the expanding role. Cornea. 2005;24:269\u201377.","journal-title":"Cornea"},{"key":"1547_CR65","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/IOP.0b013e3181d07408","volume":"27","author":"SD Shah-Desai","year":"2011","unstructured":"Shah-Desai SD, Aslam SA, Pullum K, Beaconsfield M, Rose GE. Scleral contact lens usage in patients with complex blepharoptosis. Ophthalmic Plast Reconstr Surg. 2011;27:95\u201398.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"1547_CR66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5693\/djo.01.2014.07.001","volume":"21","author":"GN Lee","year":"2015","unstructured":"Lee GN, Lin LW, Mehta S, Freitag SK. Response to phenylephrine testing in upper eyelids with ptosis. Digit J Ophthalmol. 2015;21:1\u201312.","journal-title":"Digit J Ophthalmol"},{"key":"1547_CR67","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/01.iop.0000196322.05586.6a","volume":"22","author":"DC Garibaldi","year":"2006","unstructured":"Garibaldi DC, Hindman HB, Grant MP, Iliff NT, Merbs SL. Effect of 0.5% apraclonidine on ptosis in Horner syndrome. Ophthal Plast Reconstr Surg. 2006;22:53\u201355.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"1547_CR68","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/IOP.0000000000000843","volume":"34","author":"CA Kirkpatrick","year":"2018","unstructured":"Kirkpatrick CA, Shriver EM, Clark TE, Kardon RH. Upper eyelid response to topical 0.5% apraclonidine. Ophthal Plast Reconstr Surg. 2018;34:13\u201319.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"1547_CR69","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/bjo.79.12.1098","volume":"79","author":"SV Araujo","year":"1995","unstructured":"Araujo SV, Bond JB, Wilson RP, Moster MR, Schmidt CM Jr., Spaeth GL. Long term effect of apraclonidine. Br J Ophthalmol. 1995;79:1098\u2013101.","journal-title":"Br J Ophthalmol"},{"key":"1547_CR70","first-page":"421","volume":"93","author":"AL Robin","year":"1995","unstructured":"Robin AL, Ritch R, Shin D, Smythe B, Mundorf T, Lehmann RP. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group. Trans Am Ophthalmol Soc. 1995;93:421\u201338.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1547_CR71","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/archopht.1995.01100030041019","volume":"113","author":"WC Stewart","year":"1995","unstructured":"Stewart WC, Ritch R, Shin DH, Lehmann RP, Shrader CE, van Buskirk EM. The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group. Arch Ophthalmol. 1995;113:287\u201392.","journal-title":"Arch Ophthalmol"},{"key":"1547_CR72","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/DSS.0000000000000967","volume":"43","author":"TB Mendon\u00e7a","year":"2017","unstructured":"Mendon\u00e7a TB, Lummertz AP, Bocaccio FJ, Procianoy F. Effect of low-concentration, nonmydriatic selective alpha-adrenergic agonist eyedrops on upper eyelid position. Dermatol Surg. 2017;43:270\u20134.","journal-title":"Dermatol Surg"},{"key":"1547_CR73","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1600-0404.1993.tb05516.x","volume":"87","author":"A Uncini","year":"1993","unstructured":"Uncini A, De Nicola G, Di Muzio A, Rancitelli G, Colangelo L, Gambi D, et al. Topical naphazoline in treatment of myopathic ptosis. Acta Neurol Scand. 1993;87:322\u20134.","journal-title":"Acta Neurol Scand"},{"key":"1547_CR74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mus.22002","volume":"44","author":"Y Nagane","year":"2011","unstructured":"Nagane Y, Utsugisawa K, Suzuki S, Masuda M, Shimizu Y, Utsumi H, et al. Topical naphazoline in the treatment of myasthenic blepharoptosis. Muscle Nerve. 2011;44:41\u201344.","journal-title":"Muscle Nerve"},{"key":"1547_CR75","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/WNO.0000000000000826","volume":"40","author":"A Rehmani","year":"2020","unstructured":"Rehmani A, Mehta I, Smith E. Treatment of ptosis using brimonidine tartrate for anterior laminectomy-induced Horner syndrome. J Neuroophthalmol. 2020;40:95\u201396.","journal-title":"J Neuroophthalmol"},{"key":"1547_CR76","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/OPTO.S259398","volume":"12","author":"LO Hosten","year":"2020","unstructured":"Hosten LO, Snyder C. Over-the-counter ocular decongestants in the United States - mechanisms of action and clinical utility for management of ocular redness. Clin Optom. 2020;12:95\u2013105.","journal-title":"Clin Optom"},{"key":"1547_CR77","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/OPX.0000000000001182","volume":"95","author":"E McLaurin","year":"2018","unstructured":"McLaurin E, Cavet ME, Gomes PJ, Ciolino JB. Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial. Optom Vis Sci. 2018;95:264\u201371.","journal-title":"Optom Vis Sci"},{"key":"1547_CR78","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/archopht.1997.01100160017002","volume":"115","author":"JS Schuman","year":"1997","unstructured":"Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997;115:847\u201352.","journal-title":"Arch Ophthalmol"},{"key":"1547_CR79","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1472-8206.2009.00805.x","volume":"24","author":"B Haenisch","year":"2010","unstructured":"Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, et al. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharm. 2010;24:729\u201339.","journal-title":"Fundam Clin Pharm"},{"key":"1547_CR80","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/j.1476-5381.1996.tb15530.x","volume":"118","author":"D Sugden","year":"1996","unstructured":"Sugden D, Anwar N, Klein D. Rat pineal \u03b11-adrenoceptor subtypes: studies using radioligand binding and reverse transcription-polymerase chain reaction analysis. Br J Pharm. 1996;118:1246\u201352.","journal-title":"Br J Pharm"},{"key":"1547_CR81","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1001\/jamaophthalmol.2020.3812","volume":"138","author":"CB Slonim","year":"2020","unstructured":"Slonim CB, Foster S, Jaros M, Kannarr SR, Korenfeld MS, Smyth-Medina R, et al. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2020;138:1168\u201375.","journal-title":"JAMA Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01547-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01547-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01547-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T22:41:59Z","timestamp":1672008119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01547-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1547"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01547-5","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"11 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JB reports speaker fees from Aerie Pharmaceuticals, Alcon, Allergan, Bausch & Lomb, Glaukos, New World Medical, and Sun Pharmaceutical Industries, Inc.; consultant fees from Aerie Pharmaceuticals, Alcon, Allergan, Bausch & Lomb, Injectsense, New World Medical, Optovue, and Osmotica Pharmaceuticals; personal fees from Sun Pharmaceutical Industries, Inc.; and research support from Aerie Pharmaceuticals, Allergan, Novartis, Glaukos, Optovue, and Ocular Therapeutix. WWL reports consultant fees from Allergan, Galderma, Horizon Pharmaceuticals, Mallinckrodt, Osmotica Pharmaceuticals, Revance, and Solta. ARH reports consultant fees from Osmotica Pharmaceuticals and Horizon Pharmaceuticals; and speaker fees from Horizon Pharmaceuticals. TFF reports consultant fees from Osmotica Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}